John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pinto MD, Greenblatt AM, Williams BL, Kaplin AI. Exploring the mechanism of the clinical encounter on depressive symptoms in young adults: a path analysis. Issues Ment Health Nurs. 2017 Jul;38(7):533-9. doi: 10.1080/01612840.2017.1305023.
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Greenblatt AM, Pinto MD, Higgins MK, Berg CJ. Exploring the relationships among level of contact, nature of contact, and mental illness stigma in adolescent girls. Issues Ment Health Nurs. 2016 Jan;37(1):10-8. doi: 10.3109/01612840.2015.1087604
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Williams RE, Bosnic N, Sweeney CT, Duncan AW, Levine KB, Brogan M, Cook SF. Prevalence of opioid dispensings and concurrent gastrointestinal medications in Quebec. Pain Res Manag. 2008;13(5):395-400.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.